Sign inJoin waitlistJoin the waitlist

JC

Jamie Chaft

Attending Physician · New York Presbyterian Hospital

Credentials: · · · ·

History

Memorial Sloan Kettering Monmouth
2021–Present

Memorial Sloan Kettering Cancer Center
2009–2011
New York Presbyterian Hospital
2006–2009
New York University Grossman School of Medicine
2002–2006

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
New England Journal of Medicine · 2018 · 1,667 citations
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled…
Journal of Clinical Oncology · 2018 · 1,159 citations

MK
Mark Kris
63 papers
MH
Matthew Hellmann
43 papers · 4 as a fellow
AR
Andreas Rimner
33 papers
DJ
David Jones
33 papers
Daniel Gomez
32 papers
GR
Gregory Riely
31 papers
NS
Narek Shaverdian
29 papers
Charles Rudin
27 papers
Valerie Rusch
27 papers
AW
Abraham Wu
25 papers
ML
Marc Ladanyi
21 papers
DG
Daphna Gelblum
20 papers

Grants

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT
National Cancer Institute · U01
PI · $1.1M · Sloan-Kettering Inst Can Research
2012–2016

Clinical trials

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 3
AstraZeneca
2020–2029
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2016–2026
Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2016–2026
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Principal investigator · Withdrawn · Phase 1
Memorial Sloan Kettering Cancer Center
2013–2015